<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    16554525
   </pmid>
   <datecreated>
    <year>
     2006
    </year>
    <month>
     03
    </month>
    <day>
     23
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2006
    </year>
    <month>
     04
    </month>
    <day>
     07
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2007
    </year>
    <month>
     11
    </month>
    <day>
     14
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Electronic">
      1533-4406
     </issn>
     <journalissue citedmedium="Internet">
      <volume>
       354
      </volume>
      <issue>
       12
      </issue>
      <pubdate>
       <year>
        2006
       </year>
       <month>
        Mar
       </month>
       <day>
        23
       </day>
      </pubdate>
     </journalissue>
     <title>
      The New England journal of medicine
     </title>
     <isoabbreviation>
      N. Engl. J. Med.
     </isoabbreviation>
    </journal>
    <articletitle>
     Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.
    </articletitle>
    <pagination>
     <medlinepgn>
      1231-42
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="BACKGROUND" nlmcategory="BACKGROUND">
      After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another.
     </abstracttext>
     <abstracttext label="METHODS" nlmcategory="METHODS">
      We randomly assigned 727 adult outpatients with a nonpsychotic major depressive disorder who had no remission of symptoms or could not tolerate the SSRI citalopram to receive one of the following drugs for up to 14 weeks: sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg, sertraline (238 patients) at a maximal daily dose of 200 mg, or extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg. The study was conducted in 18 primary and 23 psychiatric care settings. The primary outcome was symptom remission, defined by a total score of 7 or less on the 17-item Hamilton Rating Scale for Depression (HRSD-17) at the end of the study. Scores on the Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR-16), obtained at treatment visits, determined secondary outcomes, including remission (a score of 5 or less at exit) and response (a reduction of 50 percent or more on baseline scores).
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      Remission rates as assessed by the HRSD-17 and the QIDS-SR-16, respectively, were 21.3 percent and 25.5 percent for sustained-release bupropion, 17.6 percent and 26.6 percent for sertraline, and 24.8 percent and 25.0 percent for extended-release venlafaxine. QIDS-SR-16 response rates were 26.1 percent for sustained-release bupropion, 26.7 percent for sertraline, and 28.2 percent for extended-release venlafaxine. These treatments did not differ significantly with respect to outcomes, tolerability, or adverse events.
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant. Any one of the medications in the study provided a reasonable second-step choice for patients with depression. (ClinicalTrials.gov number, NCT00021528.).
     </abstracttext>
     <copyrightinformation>
      Copyright 2006 Massachusetts Medical Society.
     </copyrightinformation>
    </abstract>
    <affiliation>
     Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390-9086, USA. john.rush@utsouthwestern.edu
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Rush
      </lastname>
      <forename>
       A John
      </forename>
      <initials>
       AJ
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Trivedi
      </lastname>
      <forename>
       Madhukar H
      </forename>
      <initials>
       MH
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Wisniewski
      </lastname>
      <forename>
       Stephen R
      </forename>
      <initials>
       SR
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Stewart
      </lastname>
      <forename>
       Jonathan W
      </forename>
      <initials>
       JW
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Nierenberg
      </lastname>
      <forename>
       Andrew A
      </forename>
      <initials>
       AA
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Thase
      </lastname>
      <forename>
       Michael E
      </forename>
      <initials>
       ME
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Ritz
      </lastname>
      <forename>
       Louise
      </forename>
      <initials>
       L
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Biggs
      </lastname>
      <forename>
       Melanie M
      </forename>
      <initials>
       MM
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Warden
      </lastname>
      <forename>
       Diane
      </forename>
      <initials>
       D
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Luther
      </lastname>
      <forename>
       James F
      </forename>
      <initials>
       JF
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Shores-Wilson
      </lastname>
      <forename>
       Kathy
      </forename>
      <initials>
       K
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Niederehe
      </lastname>
      <forename>
       George
      </forename>
      <initials>
       G
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Fava
      </lastname>
      <forename>
       Maurizio
      </forename>
      <initials>
       M
      </initials>
     </author>
     <author validyn="Y">
      <collectivename>
       STAR*D Study Team
      </collectivename>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <databanklist completeyn="Y">
     <databank>
      <databankname>
       ClinicalTrials.gov
      </databankname>
      <accessionnumberlist>
       <accessionnumber>
        NCT00021528
       </accessionnumber>
      </accessionnumberlist>
     </databank>
    </databanklist>
    <grantlist completeyn="Y">
     <grant>
      <grantid>
       N01MH90003
      </grantid>
      <acronym>
       MH
      </acronym>
      <agency>
       NIMH NIH HHS
      </agency>
      <country>
       United States
      </country>
     </grant>
    </grantlist>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Multicenter Study
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, N.I.H., Extramural
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     N Engl J Med
    </medlineta>
    <nlmuniqueid>
     0255562
    </nlmuniqueid>
    <issnlinking>
     0028-4793
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Antidepressive Agents, Second-Generation
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Cyclohexanols
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Delayed-Action Preparations
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Serotonin Uptake Inhibitors
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      34841-39-9
     </registrynumber>
     <nameofsubstance>
      Bupropion
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      79617-96-2
     </registrynumber>
     <nameofsubstance>
      Sertraline
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      93413-69-5
     </registrynumber>
     <nameofsubstance>
      venlafaxine
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="CommentIn">
     <refsource>
      N Engl J Med. 2006 Mar 23;354(12):1305-7
     </refsource>
     <pmid version="1">
      16554533
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Evid Based Ment Health. 2006 Nov;9(4):100
     </refsource>
     <pmid version="1">
      17065297
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      N Engl J Med. 2006 Jun 15;354(24):2611-3; author reply 2611-3
     </refsource>
     <pmid version="1">
      16775243
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Antidepressive Agents, Second-Generation
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Bupropion
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Cyclohexanols
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Delayed-Action Preparations
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Depressive Disorder, Major
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Remission Induction
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Serotonin Uptake Inhibitors
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Sertraline
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Time Factors
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Treatment Failure
     </descriptorname>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2006
     </year>
     <month>
      3
     </month>
     <day>
      24
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2006
     </year>
     <month>
      4
     </month>
     <day>
      8
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2006
     </year>
     <month>
      3
     </month>
     <day>
      24
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pii">
     354/12/1231
    </articleid>
    <articleid idtype="doi">
     10.1056/NEJMoa052963
    </articleid>
    <articleid idtype="pubmed">
     16554525
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

